As discussed below, ANXA7 may act as an oncogene in gastric cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and breast cancer; or as an oncosuppressor in melanoma, prostate cancer, and glioblastoma. Here, ANXA7 is linked to gastric cancer.